Liver-gut Axis Study Through Identification of Liver Disease-specific Microbiome

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

RECRUITING

Total Enrollment

3000 participants

Study Classification

OBSERVATIONAL

Study Start Date

2024-07-08

Study Completion Date

2029-07-08

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

In this study, we aim to identify gut microbiomes specific to patients with chronic refractory liver disease and to conduct a gut-liver axis study on the pathogenesis and disease progression.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Assessment of Microorganisms and Host Response In Liver Diseases

NCT06291571

Gut Microbiome Liver Diseases

NOT_YET_RECRUITING

Gut Microbiota Metagenomics for Chronic Liver Disease

NCT04339725

Liver Disease Chronic

UNKNOWN

Compositional Shift of Gut Microbiome According to the Complications in Patients With Liver Cirrhosis

NCT05786755

Liver Cirrhosis

COMPLETED

Effectiveness and Safety of the COVID-19 Vaccination for Patients With Liver Disease (CHESS2101)

NCT04883177

COVID-19 Liver Disease Vaccine Reaction

COMPLETED

Gut Microbiota and Modulation of Liver Damage in NAFLD

NCT02158351

Simple Steatosis (SS) Non-alcoholic Steatohepatitis (NASH) Obesity

COMPLETED

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

1. The investigators will recruit study participants aged 19 and older who have been diagnosed with autoimmune hepatitis, primary biliary cholangitis, primary sclerosing cholangitis, non-alcoholic steatohepatitis, or liver abscess, along with their household members, and who have agreed to participate in this study at Chungnam National University Hospital.
2. The investigators collect and analyze blood and stool samples from the patients and their household members
3. Sampling Method: Non-Probability Samples
4. Study Population:

Group of autoimmune hepatitis: patients with definite autoimmune hepatitis or their healthy households for controls Group of primary biliary cholangitis: patients with definite primary biliary cholangitis or their healthy households for controls Group of primary sclerosing cholangitis: patients with definite primary sclerosing cholangitis or their healthy households for controls Group of non-alcoholic steatohepatitis: patients with definite non-alcoholic steatohepatitis or their healthy households for controls Group of liver abscess: patients with definite liver abscess or their healthy households for controls.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Autoimmune Hepatitis Primary Sclerosing Cholangitis Non-Alcoholic Fatty Liver Disease Liver Abscess Primary Biliary Cirrhosis

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

CASE_CONTROL

Study Time Perspective

PROSPECTIVE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Adults aged 19 years and older diagnosed with autoimmune hepatitis, primary biliary cholangitis, primary sclerosing cholangitis, non-alcoholic fatty liver disease, or liver abscess, who have consented to participate in this study at Chungnam National University Hospital.
* Adults aged 19 years and older, who are cohabitants of patients diagnosed with autoimmune hepatitis, primary biliary cholangitis, primary sclerosing cholangitis, non-alcoholic fatty liver disease, or liver abscess, and have consented to participate in this study at Chungnam National University Hospital.

B. Exclusion